299660.KQ
Cellid, Co., Ltd.
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 2,405.00
−1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.4B | 8.8B | 4.2B | — | 480.0M |
| Cost of Revenue | 9.9B | 9.8B | 3.5B | 2.7B | 2.9B |
| Gross Profit | 532.0M | (939.3M) | 705.0M | (2.7B) | (2.4B) |
| Operating Expenses | |||||
| R&D Expense | 4.1B | 4.0B | 3.5B | 5.0B | 7.9B |
| SG&A Expense | 4.5B | 3.6B | 3.5B | 4.8B | 4.7B |
| General & Admin Expense | 876.4M | 1.3B | 1.6B | 629.6M | 638.4M |
| Selling & Marketing Expense | 2.0B | 2.2B | 1.9B | 927.2M | 852.2M |
| Other Expenses | 4.7B | 3.2B | 5.7B | 2.4B | (55.8M) |
| Total Operating Expenses | 11.4B | 10.8B | 12.7B | 12.2B | 12.5B |
| Cost and Expenses | 21.3B | 20.5B | 16.1B | 12.2B | 15.4B |
| Operating Income (EBIT) | (10.9B) | (11.7B) | (12.0B) | (12.2B) | (14.9B) |
| Non-Operating | |||||
| Interest Income | 519.9M | 323.4M | 448.1M | 631.0M | 955.9M |
| Interest Expense | 425.7M | 142.5M | 472.0M | 1.3B | 1.6B |
| Net Interest Income | 94.2M | 180.9M | (23.9M) | (631.0M) | (672.4M) |
| Other Non-Op Income/Expense | (16.5B) | (363.6M) | (278.5M) | 586.5M | (8.0B) |
| Non-Operating Income (excl Interest) | 644.4M | — | (193.4M) | (1.9B) | 6.3B |
| EBT (Pre-Tax Income) | (27.4B) | (12.1B) | (12.3B) | (11.6B) | (22.9B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (27.4B) | (12.1B) | (12.3B) | (11.6B) | (22.9B) |
| Earnings from Cont. Ops | (27.4B) | (12.1B) | (12.3B) | (11.6B) | (22.9B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.4B) | (12.1B) | (12.3B) | (11.6B) | (22.9B) |
| Per Share | |||||
| Basic EPS | (₩928) | (₩409) | (₩695) | (₩1,078) | (₩2,350) |
| Diluted EPS | (₩928) | (₩409) | (₩695) | (₩1,078) | (₩2,350) |
| Revenue Per Share | ₩353 | ₩300 | ₩236 | ₩0 | ₩49 |
| Shares | |||||
| Basic Shares Outstanding | 29.5M | 29.5M | 17.6M | 10.8M | 9.7M |
| Diluted Shares Outstanding | 29.5M | 29.5M | 17.6M | 10.8M | 9.7M |
| Profitability Metrics | |||||
| EBITDA | (8.7B) | (9.2B) | (9.1B) | (7.7B) | (18.6B) |
| D&A | 2.0B | 2.5B | 2.7B | 2.7B | 2.6B |
| EBIT | (10.7B) | (11.7B) | (11.8B) | (10.3B) | (21.2B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026